Jeffrey S. Farrow - 15 Mar 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Financial Officer and Chief Strategy Officer
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 15 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 18 Mar 2025, 21:40:39 UTC
Previous filing: 07 Mar 2025
Next filing: 20 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Options Exercise		+8,019	+44%		26,155	15 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Restricted Stock Units	Options Exercise	$0	-8,019	-25%	$0.000000	24,060	17 Mar 2025	Common Stock	8,019		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2	Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3	RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

Remarks:

Chief Financial Officer and Chief Strategy Officer